Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

 
• By Jessica Merrill
  
Business success concept with target as motivation (3D Rendering) - Illustration
Acadia's pimavanserin trial was stopped early due to efficacy in dementia-related psychosis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapy Areas